5-minute watch
EHA expert perspective
Global variation in CAR T-Cell therapy practice patterns for LBCL: Quantitative research findings
5-minute watch
EHA expert perspective
International expert consensus on real-world CAR T-Cell eligibility in large B-Cell Lymphomas
14-minute watch
Comparative and Indirect Evidence
Comparative and Indirect Evidence: Meta‑Analysis and Network Meta‑Analysis
18-minute watch
Comparative and Indirect Evidence
Comparative and Indirect Evidence: Indirect Comparisons and MAIC
18-minute watch
Comparative and Indirect Evidence
Comparative and Indirect Evidence: Propensity Scoring
14-minute watch
Understanding Treatment Effects in Subgroups
Understanding Treatment Effects in Subgroups: Subgroup Evaluation
22-minute watch
Controlling Error and Interpretation Risk
Controlling Error and Interpretation Risk: Interim Analyses
15-minute watch
Controlling Error and Interpretation Risk
Controlling Error and Interpretation Risk: Multiplicity 2
20-minute watch
Advanced Modelling and Data Analysis
Advanced Modelling and Data Analysis: Estimands
23-minute watch
Advanced Modelling and Data Analysis
Advanced Modelling and Data Analysis: Analysis Populations and Missing Data
20-minute watch
Advanced Modelling and Data Analysis
Advanced Modelling and Data Analysis: Regression Modelling
17-minute watch
Foundations of Clinical Trial Statistics
Foundations of Clinical Trial Statistics: Power and Sample Size
13-minute watch
Foundations of Clinical Trial Statistics
Foundations of Clinical Trial Statistics: Study Endpoints and Analysis
12-minute watch
Foundations of Clinical Trial Statistics
Foundations of Clinical Trial Statistics: Randomisation and Stratification
18-minute watch
Foundations of Clinical Trial Statistics
Foundations of Clinical Trial Statistics: p‑Values and Confidence Intervals
14-minute watch
Time‑to‑Event and Survival Analysis
Time‑to‑Event and Survival Analysis: Kaplan–Meier Curves 2
16-minute watch
Time‑to‑Event and Survival Analysis
Time‑to‑Event and Survival Analysis: Hazard Ratios
9-minute watch
Time‑to‑Event and Survival Analysis
Time‑to‑Event and Survival Analysis: Kaplan–Meier Curves 1
2-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL
Conclusion and closing remarks
12-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL
Navigating life after CAR T, Part II: Patient experience and long-term well-being
8-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL
Navigating life after CAR T, Part I: Patient experience and long-term well-being
16-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL
Evolving strategies: Acute and long-term adverse event management
18-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL
Building the foundation: Strategies to optimise patient outcomes
5-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL
Welcome and introduction
2-minute watch
DELIVERING OUTCOMES, NOT JUST CELLS: Why speed and reliability matter for CAR T patients
Conclusion and closing remarks
18-minute watch
DELIVERING OUTCOMES, NOT JUST CELLS: Why speed and reliability matter for CAR T patients
From referral to recovery: Optimising the CAR T patient journey
8-minute watch
DELIVERING OUTCOMES, NOT JUST CELLS: Why speed and reliability matter for CAR T patients
Speed and reliability: Shaping CAR T outcomes
6-minute watch
DELIVERING OUTCOMES, NOT JUST CELLS: Why speed and reliability matter for CAR T patients
Welcome and introduction
17-minute watch
EBMT 2026
Misconception: My patient isn’t the ‘right’ patient for CAR T
15-minute watch
EBMT 2026
Misconception: The CAR T journey is too long for my patient to complete
22-minute watch
EBMT 2026
Misconception: The side effects of CAR T are too severe
10-minute watch
EU CAR T 2026
Building confidence with evidence: Real-world insights into CAR T management
5-minute watch
EU CAR T 2026
The speed advantage: Exploring how rapid and reliable manufacturing impacts patient care
18-minute watch
Medical Statistics at a Glance
Comparative Analyses: Propensity Scoring
19-minute watch
Medical Statistics at a Glance
Comparative Analyses: Indirect Comparisons and MAIC
14-minute watch
Medical Statistics at a Glance
Comparative Analyses: Meta Analysis and Network Meta Analysis
4-minute watch
ASH 2025: Expert Perspective
Visualizing Geographic Variation and Systemic Inequities of Disease Burden and CAR T-Cell Therapy Access in Multiple Myeloma in the US
4-minute watch
ASH 2025: Expert Perspective
Real-World Healthcare Resource Utilization (HCRU) Following CAR T-Cell Therapy in US Patients treated in Newly Authorized Treatment Centers
21-minute watch
EHA 2025
Age is not a barrier: The older patient with comorbidities
24-minute watch
EHA 2025
Timing is of the essence: The patient with MCL on a BTKi
8-minute watch
EBMT 2025
Charting a course in the CAR T age: SoC in 2L R/R DLBCL
8-minute watch
EU CAR T 2025 Is a cure in R/R lymphomas on the horizon?
Optimising patient outcomes in CAR T care
8-minute watch
EU CAR T 2025 Is a cure in R/R lymphomas on the horizon?
Are we moving towards a cure in R/R lymphoma?
11-minute watch
EU CAR T 2025 Is a cure in R/R lymphomas on the horizon?
CAR T in practice: Insights and implications from real-world data
10-minute watch
EHA: How is CAR T evolving?
Why should CAR T be used earlier in R/R DLBCL?
11-minute watch
EHA: How is CAR T evolving?
What does the future hold for CAR T manufacturing?
13-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
CAR T survivorship and summary
18-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Choosing CAR T with curative intent
10-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Delivering CAR T
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Planning ahead for 2L
14-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist
24-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
How can we bring CAR T
14-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
What is the most appropriate treatment choice in 2L LBCL? A case-based approach
20-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
Why has CAR T become the SoC in 2L LBCL?
15-minute watch
EU CAR T: Kite symposium
How can we improve survival outcomes in R/R LBCL?
15-minute watch
EU CAR T: Kite symposium
How has CAR T changed survival outcomes in LBCL so far?
5-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy
How can we address reimbursement challenges for CAR T?
4-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy
Why is timely reimbursement of CAR T important for our patients?
3-minute watch
EU CAR T: Expert Perspective
Secondary malignancies after Car T-cell therapy
5-minute watch
ASH 2024
Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
3-minute watch
ASH 2024
ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
5-minute watch
ASH 2024
CAR-Tography: getting a better understanding of acute toxicities post-CAR T
4-minute watch
ASH 2024
Can interim PET aid early identification of patients for CAR T?
3-minute watch
ASH 2024
What approaches are being used to prevent and mitigate CAR T toxicities?
5-minute watch
ASH 2024
How is MCL managed with CAR T? Results from the EBMT survey
19-minute watch
Controlling Error and Interpretation Risk
Controlling Error and Interpretation Risk: Multiplicity 1
12-minute watch
Medical Statistics at a Glance
Foundations of Clinical Trial Statistics: Randomisation and Stratification
18-minute watch
Medical Statistics at a Glance
Foundations of Clinical Trial Statistics: p-Values and Confidence Intervals
14-minute watch
Medical Statistics at a Glance
Time‑to‑Event and Survival Analysis: Kaplan-Meier curves 2
9-minute watch
Medical Statistics at a Glance
Time‑to‑Event and Survival Analysis: Kaplan-Meier curves 1
5-minute watch
ASH 2025: Expert Perspective
A Phase 1 Study of KITE-753 or KITE-363 in Patients with Relapsed/Refractory B-Cell Lymphoma
5-minute watch
ASH 2025: Expert Perspective
Blood and CDF Metabolomics Identifies Tryptophan Catabolism and Polyamine Synthesis as Drivers of CAR T Cell-Associated Neurotoxicity
GFM-UNB-1778 November 2025
GFM-UNB-1778 November 2025